Cargando…

A review of Cochrane reviews on pharmacological treatment for attention deficit hyperactivity disorder

Attention deficit hyperactivity disorder (ADHD) is one of the most frequent childhood psychiatric problems. OBJECTIVE: The objective of this study was to identify, synthesize the results, and critically evaluate all Cochrane systematic reviews (SRs) on the pharmacological interventions for children...

Descripción completa

Detalles Bibliográficos
Autores principales: Santos, Giovanna Marcílio, Santos, Elaine Marcílio, Mendes, Gustavo Duarte, Fragoso, Yara Dadalti, Souza, Mariani Rafaela, Martimbianco, Ana Luiza Cabrera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Associação de Neurologia Cognitiva e do Comportamento 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018091/
https://www.ncbi.nlm.nih.gov/pubmed/35509804
http://dx.doi.org/10.1590/1980-57642021dn15-040001
_version_ 1784688934889979904
author Santos, Giovanna Marcílio
Santos, Elaine Marcílio
Mendes, Gustavo Duarte
Fragoso, Yara Dadalti
Souza, Mariani Rafaela
Martimbianco, Ana Luiza Cabrera
author_facet Santos, Giovanna Marcílio
Santos, Elaine Marcílio
Mendes, Gustavo Duarte
Fragoso, Yara Dadalti
Souza, Mariani Rafaela
Martimbianco, Ana Luiza Cabrera
author_sort Santos, Giovanna Marcílio
collection PubMed
description Attention deficit hyperactivity disorder (ADHD) is one of the most frequent childhood psychiatric problems. OBJECTIVE: The objective of this study was to identify, synthesize the results, and critically evaluate all Cochrane systematic reviews (SRs) on the pharmacological interventions for children and adolescents (up to age 18) diagnosed with ADHD. METHODS: The search was performed in the Cochrane Database of Systematic Reviews (via Wiley) in July 2020. RESULTS: The search strategy resulted in four SRs of high methodological quality, analyzing 51 randomized clinical trials (9,013 participants). Compared to placebo, treatment with tricyclic antidepressants (TCAs) (desipramine), amphetamine, and methylphenidate showed improvement in symptoms such as difficulty concentrating, impulsivity, and hyperactivity in the short term (up to 6 months). There was an increase in the occurrence of adverse events, such as reduced appetite, difficulty sleeping, and abdominal pain. Insufficient evidence was found to support the effects of supplementation with polyunsaturated fatty acids. CONCLUSIONS: The use of TCAs, amphetamine, and methylphenidate in children and adolescents with ADHD seems to present positive effects and higher rates of minor adverse events when compared to placebo.
format Online
Article
Text
id pubmed-9018091
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Associação de Neurologia Cognitiva e do Comportamento
record_format MEDLINE/PubMed
spelling pubmed-90180912022-05-03 A review of Cochrane reviews on pharmacological treatment for attention deficit hyperactivity disorder Santos, Giovanna Marcílio Santos, Elaine Marcílio Mendes, Gustavo Duarte Fragoso, Yara Dadalti Souza, Mariani Rafaela Martimbianco, Ana Luiza Cabrera Dement Neuropsychol Original Article Attention deficit hyperactivity disorder (ADHD) is one of the most frequent childhood psychiatric problems. OBJECTIVE: The objective of this study was to identify, synthesize the results, and critically evaluate all Cochrane systematic reviews (SRs) on the pharmacological interventions for children and adolescents (up to age 18) diagnosed with ADHD. METHODS: The search was performed in the Cochrane Database of Systematic Reviews (via Wiley) in July 2020. RESULTS: The search strategy resulted in four SRs of high methodological quality, analyzing 51 randomized clinical trials (9,013 participants). Compared to placebo, treatment with tricyclic antidepressants (TCAs) (desipramine), amphetamine, and methylphenidate showed improvement in symptoms such as difficulty concentrating, impulsivity, and hyperactivity in the short term (up to 6 months). There was an increase in the occurrence of adverse events, such as reduced appetite, difficulty sleeping, and abdominal pain. Insufficient evidence was found to support the effects of supplementation with polyunsaturated fatty acids. CONCLUSIONS: The use of TCAs, amphetamine, and methylphenidate in children and adolescents with ADHD seems to present positive effects and higher rates of minor adverse events when compared to placebo. Associação de Neurologia Cognitiva e do Comportamento 2021 /pmc/articles/PMC9018091/ /pubmed/35509804 http://dx.doi.org/10.1590/1980-57642021dn15-040001 Text en https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License
spellingShingle Original Article
Santos, Giovanna Marcílio
Santos, Elaine Marcílio
Mendes, Gustavo Duarte
Fragoso, Yara Dadalti
Souza, Mariani Rafaela
Martimbianco, Ana Luiza Cabrera
A review of Cochrane reviews on pharmacological treatment for attention deficit hyperactivity disorder
title A review of Cochrane reviews on pharmacological treatment for attention deficit hyperactivity disorder
title_full A review of Cochrane reviews on pharmacological treatment for attention deficit hyperactivity disorder
title_fullStr A review of Cochrane reviews on pharmacological treatment for attention deficit hyperactivity disorder
title_full_unstemmed A review of Cochrane reviews on pharmacological treatment for attention deficit hyperactivity disorder
title_short A review of Cochrane reviews on pharmacological treatment for attention deficit hyperactivity disorder
title_sort review of cochrane reviews on pharmacological treatment for attention deficit hyperactivity disorder
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018091/
https://www.ncbi.nlm.nih.gov/pubmed/35509804
http://dx.doi.org/10.1590/1980-57642021dn15-040001
work_keys_str_mv AT santosgiovannamarcilio areviewofcochranereviewsonpharmacologicaltreatmentforattentiondeficithyperactivitydisorder
AT santoselainemarcilio areviewofcochranereviewsonpharmacologicaltreatmentforattentiondeficithyperactivitydisorder
AT mendesgustavoduarte areviewofcochranereviewsonpharmacologicaltreatmentforattentiondeficithyperactivitydisorder
AT fragosoyaradadalti areviewofcochranereviewsonpharmacologicaltreatmentforattentiondeficithyperactivitydisorder
AT souzamarianirafaela areviewofcochranereviewsonpharmacologicaltreatmentforattentiondeficithyperactivitydisorder
AT martimbiancoanaluizacabrera areviewofcochranereviewsonpharmacologicaltreatmentforattentiondeficithyperactivitydisorder
AT santosgiovannamarcilio reviewofcochranereviewsonpharmacologicaltreatmentforattentiondeficithyperactivitydisorder
AT santoselainemarcilio reviewofcochranereviewsonpharmacologicaltreatmentforattentiondeficithyperactivitydisorder
AT mendesgustavoduarte reviewofcochranereviewsonpharmacologicaltreatmentforattentiondeficithyperactivitydisorder
AT fragosoyaradadalti reviewofcochranereviewsonpharmacologicaltreatmentforattentiondeficithyperactivitydisorder
AT souzamarianirafaela reviewofcochranereviewsonpharmacologicaltreatmentforattentiondeficithyperactivitydisorder
AT martimbiancoanaluizacabrera reviewofcochranereviewsonpharmacologicaltreatmentforattentiondeficithyperactivitydisorder